July 8, 2013

W. Haven biotech signs British R&D deal

NanoViricides Inc. is working with British health officials to develop treatments targeting two deadly diseases, the company said.

The West Haven development-stage biotech signed a confidential disclosure agreement with Public Health England (which is the British equivalent of the U.S. Center for Disease Control) to develop a proposal to test nanoviricides on the H7N9 influenza virus and the MERS virus.

The former is circulating in China and the latter has spread in the Middle East. Both viruses have high fatality rates.

Nanoviricides, as explained on the company's website, fool a virus into attaching to a "nanomachine," which then wraps around the virus and destroys it.

Image credit: www.freedigitalphotos.net

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Will the Obamacare delay impact your business?<>
Most Popular on Facebook
Copyright 2017 New England Business Media